for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Erytech Pharma SA

ERYP.PA

Latest Trade

4.72EUR

Change

0.09(+1.94%)

Volume

9,796

Today's Range

4.64

 - 

4.79

52 Week Range

3.40

 - 

8.94

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

Erytech 9-Month Net Loss Widens To EUR 43.3 Mln

Nov 8 (Reuters) - Erytech Pharma SA <ERYP.PA>::ERYTECH PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2019.9-MONTH OPERATING LOSS EUR 46.8 MLN VS LOSS OF EUR 33.6 MLN YR AGO.9-MONTH NET LOSS EUR 43.3 MLN VS LOSS OF EUR 29.6 MLN YR AGO.END-SEPT CASH POSITION EUR 81.9 MLN, vs EUR 134.4 MILLION ON DECEMBER 31, 2018.LEAD PROGRAM TRYBECA1, THE PHASE 3 TRIAL IN PANCREATIC CANCER, PROGRESSING ON PLAN.Q4 2019: SEES FIRST U.S. PATIENTS RANDOMIZED IN TRYBECA1 PHASE 3 CLINICAL TRIAL .H1 2020: SEES LAUNCH OF INVESTIGATOR SPONSORED PHASE 1 TRIAL IN FIRST-LINE METASTATIC PANCREATIC CANCER.H1 2020: SEES INTERIM RESULTS OF INVESTIGATOR SPONSORED PHASE 2 TRIAL IN SECOND-LINE ACUTE LYMPHOBLASTIC LEUKEMIA .Q3 2020: SEES INTERIM (SUPERIORITY) ANALYSIS IN TRYBECA1.

Erytech Pharma H1 Net Loss Widens To 29.3 Million Euros

Sept 18 (Reuters) - ERYTECH PHARMA <ERYP.PA>: :REPORTED ON TUESDAY H1 NET LOSS EUR 29.3 MLN VS LOSS EUR 19.0 MLN YEAR AGO.H1 TOTAL OPERATING LOSS EUR 30.2 MLN VS LOSS EUR 21.9 MLN YEAR AGO.DR. JEAN PAUL KRESS APPOINTED AS CHAIRMAN.TRYBECA1, PHASE 3 TRIAL FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER, PROGRESSING ON PLAN.CASH POSITION OF EUR 94.5 MILLION AT THE END OF JUNE.

Erytech Pharma SA Files For Stock Shelf Of Upto $100 Mln

July 16 (Reuters) - Erytech Pharma SA <ERYP.PA>::ERYTECH PHARMA SA FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING.

Erytech Announces Immune Modulation Strategic Collaboration With SQZ Biotechnologies

June 25 (Reuters) - ERYTECH PHARMA SA <ERYP.PA>::ERYTECH ANNOUNCED ON MONDAY IT HAS ENTERED INTO AN AGREEMENT WITH SQZ BIOTECHNOLOGIES TO ADVANCE NOVEL RBC-BASED THERAPEUTICS FOR IMMUNE MODULATION.ERYTECH HAS GRANTED TO SQZ AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP ANTIGEN-SPECIFIC IMMUNE MODULATING THERAPIES EMPLOYING RBC-BASED APPROACHES.ERYTECH IS ELIGIBLE TO RECEIVE UP TO $57 MLN IN COMBINED UPFRONT AND POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS FOR FIRST PRODUCT SUCCESSFULLY DEVELOPED BY SQZ UNDER THIS AGREEMENT.ERYTECH ALSO ELIGIBLE TO RECEIVE SALES ROYALTIES, AND UP TO $50 MLN IN COMMERCIAL MILESTONE PAYMENTS RELATED TO EACH ADDITIONAL APPROVED PRODUCT OR APPROVED INDICATION.

Erytech Proposes Appointment Of Dr. Jean-Paul Kress As Chairman Of The Board Of Directors

May 6 (Reuters) - ERYTECH PHARMA SA <ERYP.PA>::ERYTECH PROPOSES THE APPOINTMENT OF DR. JEAN-PAUL KRESS AS CHAIRMAN OF THE BOARD OF DIRECTORS.

Erytech Pharma FY Total Operating Loss Widens To 43.6 Million Euros

March 12(Reuters) - ERYTECH PHARMA SA <ERYP.PA>::ANNOUNCED ON MONDAY, ERYTECH PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR FULL YEAR 2018.CASH POSITION OF EUR 134.4 MILLION ($153.9 MILLION) AT YEAR-END.FY TOTAL OPERATING INCOME EUR 4.4 MLN VS EUR 3.4 MLN YEAR AGO.FY NET LOSS OF EUR 38.2 MLN VS LOSS OF EUR 33.5 MLN YEAR AGO.FY TOTAL OPERATING LOSS OF EUR 43.6 MLN VS LOSS OF EUR 30.9 MLN YEAR AGO.EXPECTED OVER NEXT 12 MONTHS:FIRST PATIENT ENROLLED IN TRYBECA-2, PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL IN TNBC.EXPECTED OVER NEXT 12 MONTHS:START OF GMP PRODUCTION AT PRINCETON FACILITY AND LYON EXTENSION.EXPECTED OVER NEXT 12 MONTHS:START OF US PATIENT ENROLMENT IN TRYBECA 1, PHASE 3 TRIAL IN SECOND-LINE PANCREATIC CANCER.EXPECTED OVER NEXT 12 MONTHS:INITIATION OF PHASE 1 CLINICAL TRIAL WITH ERYMETHIONASE.

Erytech Presents Findings At European Red Cell Research Society Meeting

March 11 (Reuters) - ERYTECH PHARMA SA <ERYP.PA>::ERYTECH PRESENTS FINDINGS AT EUROPEAN RED CELL RESEARCH SOCIETY MEETING.IN AN EARLIER 141 PATIENT RANDOMIZED PHASE 2B TRIAL OF ERYASPASE IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF SECOND-LINE METASTATIC PANCREATIC CANCER, SIGNIFICANT IMPROVEMENTS IN OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL WERE OBSERVED VERSUS CHEMOTHERAPY ALONE WITH NO APPARENT INCREASE IN TOXICITY.WITH EXCEPTION OF L-ASPARAGINASE, ANALYSIS REVEALED NO SIGNIFICANT DIFFERENCE IN PROTEOMIC LANDSCAPE WHEN COMPARING PACKED RBCS, ERYCAPS®-PROCESSED RBCS WITHOUT ENZYME, AND ERYCAPS®-PROCESSED RBCS ENCAPSULATING L-ASPARAGINASE.RESULTS CONFIRM THAT ERYCAPS® PROCESS DOES NOT SIGNIFICANTLY ALTER PROPERTIES OF RBCS.RESULTS CONFIRM THAT APART FROM ENCAPSULATED DRUG SUBSTANCE, RBC-BASED THERAPEUTICS PRODUCED USING THIS PROCESS HAVE SIMILAR CHARACTERISTICS TO THAT OF UNPROCESSED PACKED RBCS.

ERYTECH Partners With New York Blood Center For Red Blood Cell Supply And Research

Nov 16 (Reuters) - ERYTECH PHARMA SA <ERYP.PA>::NEW YORK BLOOD CENTER (NYBC)TO BECOME LONG-TERM SUPPLIER OF DONOR RED BLOOD CELLS (RBC) TO ERYTECH.WILL ENABLE ERYTECH TO DIVERSIFY AND BROADEN ITS SUPPLY OF RBC SOURCE MATERIALS FOR PRODUCTION OF ERYASPASE .WILL ALSO ENABLE PRODUCTION OF FUTURE PRODUCT CANDIDATES DERIVED FROM ITS PROPRIETARY ERYCAPS PLATFORM.

Erytech Pharma 9-Month Operating Loss Widens To 34.1 Million Euros

Nov 13 (Reuters) - ERYTECH PHARMA SA <ERYP.PA>::ANNOUNCED ON MONDAY CASH POSITION OF EUR 146.9 MLN AS OF SEPT 30, 2018, COMPARED WITH EUR 185.5 MLN AS OF DEC 31, 2017.9-MONTH NET LOSS EUR 30.2 MLN, COMPARED TO LOSS OF EUR 20.8 MLN IN THE SAME PERIOD OF 2017.9-MONTH OPERATING LOSS EUR 34.1 MLN VS LOSS OF EUR 21.1 MLN YEAR AGO.9-MONTH TOTAL OPERATING INCOME EUR 2.6 MLN VS EUR 2.9 MLN YEAR AGO.PHASE 2 TRIAL IN TRIPLE-NEGATIVE BREAST CANCER TO ENROLL PATIENTS BY YEAR END.PHASE 3 TRIAL FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER ENROLLING PATIENTS.

Erytech: Enrollment Of 1st Patients In Phase 3 Clinical Trial Of Eryaspase

Sept 20 (Reuters) - ERYTECH PHARMA SA <ERYP.PA>::ERYTECH ANNOUNCES ENROLLMENT OF FIRST PATIENTS IN PHASE 3 CLINICAL TRIAL EVALUATING ERYASPASE FOR THE TREATMENT OF SECOND LINE PANCREATIC CANCER.TRYBECA1 TRIAL WILL ENROLL APPROXIMATELY 500 PATIENTS.PATIENT ENROLLMENT HAS STARTED AS PLANNED.FIRST THREE ENROLLED PATIENTS MARK INITIATION OF TRIAL IN EUROPE.EARLY NEXT YEAR, WE EXPECT SITES IN UNITED STATES WILL BEGIN ENROLLING AS WELL.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up